AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 19427180
Drug: Routine medication
RxNorm normalized name: Peace Out Acne Hero Routine KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Routine medication (control group)
Trial: 18782532
Drug: Jinlong Capsule
RxNorm normalized name: BUTYLENE GLYCOL 1.6 g in 8 g CUTANEOUS TAPE [LingLongJiuHuo Linglong Moxibustion]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Jinlong Capsule (TACE therapy plus Jinlong Capsule)
Trial: 18782532
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (TACE therapy alone)
Trial: 19476402
Drug: Risedronate 75
RxNorm normalized name: risedronate 75 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Risedronate 75 mg taken on two consecutive days each month (2CDM)
Trial: 19476402
Drug: Risedronate 5
RxNorm normalized name: risedronate 5 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Risedronate 5 mg taken once daily
Trial: 19476402
Drug: Risedronate 75
RxNorm normalized name: risedronate 75 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Risedronate 75 mg 2CDM and Risedronate 5 mg once daily
Trial: 17969893
Drug: Zhiling Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zhiling Capsule (ZLC)
Trial: 17969893
Drug: Pingxiao Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pingxiao Capsule (PXC)
Trial: 11806862
Drug: Nicotine (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nicotine (2 mg administered by inhalator)
Trial: 15232663
Drug: Itraconazole (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Itraconazole (200 mg/day)
Trial: 8874977
Drug: Ketoconazole (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketoconazole (200 mg/day)
Trial: 2328750
Drug: 750 mg
RxNorm normalized name: bran 750 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 750 mg metamizol sodium
Trial: 2328750
Drug: 1500 mg
RxNorm normalized name: inulin 1500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1500 mg metamizol sodium
Trial: 2328750
Drug: 3000 mg
RxNorm normalized name: talc 3000 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3000 mg metamizol sodium
Trial: 7307999
Drug: Isosorbide dinitrate
RxNorm normalized name: Isosorbide Dinitrate
DrugBank: Isosorbide dinitrate (DB00883)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Isosorbide dinitrate (40 mg orally in delay‐action form and 5 mg sublingually)
Trial: 6151343
Drug: Prazosin (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prazosin (2 mg)
Trial: 7307999
Drug: Dihydralazine (75
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dihydralazine (75 mg)
Trial: 7307999
Drug: Isosorbide dinitrate
RxNorm normalized name: Isosorbide Dinitrate
DrugBank: Isosorbide dinitrate (DB00883)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Isosorbide dinitrate (three times 20 mg)
Trial: 7307999
Drug: Prazosin (three
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prazosin (three times 2 mg)
Trial: 7307999
Drug: Dihydralazine (three
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dihydralazine (three times 75 mg)
Trial: 30994090
Drug: PfSPZ Vaccine
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PfSPZ Vaccine (9.0 × 10^5 sporozoites, three doses)
Trial: 30994090
Drug: PfSPZ Vaccine
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PfSPZ Vaccine (9.0 × 10^5 sporozoites, one dose)
Trial: 21070456
Drug: BoNTA injections
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: BoNTA injections
Trial: 8678514
Drug: 5-FU 10
RxNorm normalized name: 5-FU 10 MG/ML Topical Cream
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5-FU 10 mg/kg/24 hrs c.i.v. x 24 days (arm A, n = 25)
Trial: 8678514
Drug: 5-FU 20
RxNorm normalized name: 5-FU 20 MG/ML Topical Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5-FU 20 mg/kg/24 hrs c.i.v. x 4 days/w x 3 courses (arm B, n = 16)
Trial: 8678514
Drug: 5-FU 30
RxNorm normalized name: Epinephrine 0.1 MG / 5-FU 30 MG Injectable Suspension
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5-FU 30 mg/kg/24 hrs c.i.v. x 2 days/w x 4 courses (arm C, n = 25)
Trial: 30666732
Drug: MgSO4 50%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MgSO4 50% solution (MSS at 40 mg/kg BW)
Trial: 30666732
Drug: 5% dextrose
RxNorm normalized name: LMD with 5% Dextrose
DrugBank: D-glucose (DB01914)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5% dextrose solution (DS; control solution at 2 mL/kg body weight)
Trial: 24603102
Drug: Sildenafil citrate
RxNorm normalized name: Sildenafil Citrate
DrugBank: Sildenafil (DB00203)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sildenafil citrate (50 mg daily)
Trial: 19483659
Drug: MEDI-534 vaccine
RxNorm normalized name: Medi-Lyte
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MEDI-534 vaccine (10 median tissue culture infectious dose50)
Trial: 17634081
Drug: Patch test
RxNorm normalized name: Patch test product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patch test with a dilution series of 19 concentrations, duration up to 21 days
Trial: 11286826
Drug: Induction chemotherapy
RxNorm normalized name: human sputum, Bordetella pertussis infected
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Induction chemotherapy (CT) with cisplatin 60 mg/m² and epirubicin 110 mg/m² followed by radiotherapy (RT)
Trial: 11286826
Drug: Induction chemotherapy
RxNorm normalized name: human sputum, Bordetella pertussis infected
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Induction chemotherapy (CT) with cisplatin and epirubicin
Trial: 8011248
Drug: Foscarnet at
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Foscarnet at a dose of 60 mg/kg every 8 h for 14 days followed by maintenance doses of 60 or 90 mg/kg/day.
Trial: 8011248
Drug: Foscarnet at
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Foscarnet at a maintenance dose of 120 mg/kg/day.
Trial: 8011248
Drug: Foscarnet therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Foscarnet therapy compared to historic controls who terminated ganciclovir therapy.
Trial: 3192364
Drug: Amoxicillin combined
RxNorm normalized name: Amoxicillin
DrugBank: Amoxicillin (DB01060)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Amoxicillin combined with decongestive nose drops
Trial: 3192364
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of amoxicillin and drainage
Trial: 21755342
Drug: 2 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 mg/kg aminophylline
Trial: 21755342
Drug: 3 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 mg/kg aminophylline
Trial: 21755342
Drug: 4 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 mg/kg aminophylline
Trial: 21755342
Drug: 5 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mg/kg aminophylline
Trial: 21755342
Drug: aminophylline (2,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: aminophylline (2, 3, 4, 5 mg/kg)
Trial: 21755342
Drug: aminophylline (4,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: aminophylline (4, 5 mg/kg)
Trial: 18463672
Drug: Ramipril-HCT (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ramipril-HCT (20 mg q.d.)
Trial: 18463672
Drug: HCT monotherapy
RxNorm normalized name: Hydrochlorothiazide
DrugBank: Hydrochlorothiazide (DB00999)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: HCT monotherapy
Trial: 12594698
Drug: Acetylcysteine (600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acetylcysteine (600 mg twice a day 24 hr before and the day of cardiac catheterization)
Trial: 12594698
Drug: Control (intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (intravenous hydration alone)
Trial: 9549283
Drug: Cilostazol (150-200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cilostazol (150-200 mg/day)
Trial: 9549283
Drug: Warfarin (prothrombin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Warfarin (prothrombin time controlled to 15-25%)
Trial: 3708124
Drug: Buccal formulations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Buccal formulations
Trial: 3708124
Drug: Enteric coated
RxNorm normalized name: Mesasal Enteric Coated
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enteric coated ASA formulations
Trial: 10442525
Drug: Fexofenadine 60
RxNorm normalized name: fexofenadine 60 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fexofenadine 60 mg
Trial: 23033993
Drug: Concentrated fine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Concentrated fine particles from Chapel Hill air (PM(2.5)CAPs, 89.5 ± 10.7 µg/m³)
Trial: 8569136
Drug: F‐CaP (supplemented
FDA approved: no
EMA approved: no
PMDA approved: no
Description: F‐CaP (supplemented formula with Ca 87 mg/dl, P 43 mg/dl)
Trial: 8569136
Drug: F (non-supplemented
FDA approved: no
EMA approved: no
PMDA approved: no
Description: F (non-supplemented formula with Ca 62 mg/dl, P 36 mg/dl)
Trial: 2121109
Drug: 0.2 mg/kg/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.2 mg/kg/day recombinant human growth hormone (rHGH)
Trial: 31238700
Drug: Clopidogrel and
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clopidogrel and aspirin for 90 days
Trial: 21916906
Drug: Ascorbic acid
RxNorm normalized name: Ascorbic Acid
DrugBank: Ascorbic acid (DB00126)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ascorbic acid 2 g/day
Trial: 8743000
Drug: Perifoveal laser
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Perifoveal laser treatment
Trial: 1350935
Drug: roxatidine 150
RxNorm normalized name: roxatidine 150 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: roxatidine 150 mg once daily
Trial: 6424498
Drug: Alfentanil (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alfentanil (10 times the dose of fentanyl)
Trial: 22728648
Drug: Magnesium sulphate
RxNorm normalized name: Magnesium sulphate
DrugBank: Magnesium (DB14513)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Magnesium sulphate infusion (40 mg/kg for 15 min followed by 10 mg/kg/h during surgery)
Trial: 20639739
Drug: Etodolac (300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Etodolac (300 mg) - Paracetamol (500 mg) combination
Trial: 20639739
Drug: Etodolac (300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Etodolac (300 mg) alone
Trial: 10856145
Drug: Fluticasone propionate
RxNorm normalized name: Fluticasone Propionate
DrugBank: Fluticasone propionate (DB00588)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Fluticasone propionate (FP) 88 microg twice daily
Trial: 1311658
Drug: Amino acid
RxNorm normalized name: Amino Acid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amino acid solution starting on post-natal day 2 (Group A)
Trial: 1311658
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (Group B) starting amino acid solution after day 4
Trial: 3516000
Drug: Intramuscular meptazinol
RxNorm normalized name: meptazinol
DrugBank: Meptazinol (DB13478)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intramuscular meptazinol (1 mg/kg)
Trial: 3516000
Drug: Intramuscular pethidine
RxNorm normalized name: pethidine
DrugBank: Meperidine (DB00454)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intramuscular pethidine (1 mg/kg)
Trial: 30157913
Drug: Low-dose ketamine
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose ketamine (0.5 mg/kg) intravenously for 40 min during dural mater incision.
Trial: 30157913
Drug: Placebo (normal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (normal saline) administered at the same volume and infusion rate during the same time points.
Trial: 26946617
Drug: Intravenous infusion
RxNorm normalized name: intravenous infusion pump accessory
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous infusion of cervus and cucumis polypeptides
Trial: 26946617
Drug: Physical therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Physical therapy and rehabilitation exercises (Control)
Trial: 22382341
Drug: CE-224,535 (500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CE-224,535 (500 mg bid)
Trial: 19727904
Drug: 67.5 mmol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 67.5 mmol of bicarbonate daily for 3 months
Trial: 10752972
Drug: Delavirdine treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Delavirdine treatment
Trial: 8883526
Drug: Iodixanol 270
RxNorm normalized name: IODIXANOL 270mgI/ml INJ
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Iodixanol 270 mg I/ml (IOD-270)
Trial: 8883526
Drug: Iodixanol 320
RxNorm normalized name: IODIXANOL 320mgI/ml INJ
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Iodixanol 320 mg I/ml (IOD-320)
Trial: 8883526
Drug: Iohexol 300
RxNorm normalized name: IOHEXOL 300MG/ML INJ
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Iohexol 300 mg I/ml (IOH-300)
Trial: 3984919
Drug: 90 mg
RxNorm normalized name: papain 90 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 90 mg of ascorbic acid for 1 day followed by 250 mg/day for 2 days
Trial: 3984919
Drug: 90 mg
RxNorm normalized name: papain 90 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 90 mg of ascorbic acid for 1 day followed by 500 mg/day for 2 days
Trial: 3984919
Drug: 90 mg
RxNorm normalized name: papain 90 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 90 mg of ascorbic acid for 1 day followed by 1000 mg/day for 2 days
Trial: 3984919
Drug: unsupplemented for
FDA approved: no
EMA approved: no
PMDA approved: no
Description: unsupplemented for 1 day followed by 0 mg ascorbic acid supplement for 2 days
Trial: 3984919
Drug: unsupplemented for
FDA approved: no
EMA approved: no
PMDA approved: no
Description: unsupplemented for 1 day followed by 90 mg ascorbic acid supplement for 2 days
Trial: 30894226
Drug: Cerebral tissue
RxNorm normalized name: Sus scrofa cerebral cortex preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cerebral tissue oxygen saturation (crSO2) monitoring combined with defined treatment guidelines
Trial: 30894226
Drug: Standard monitoring
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard monitoring and treatment as usual
Trial: 30894226
Drug: Defined treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Defined treatment guidelines
Trial: 25539986
Drug: Microinjections of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Microinjections of HA salts of biotechnological origin, once weekly for 4 weeks and then once monthly for 4 months (group A) or 9 months (group B)
Trial: 25539986
Drug: Microinjections of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Microinjections of HA salts of biotechnological origin, after an additional 4 months of monthly injections
Trial: 25539986
Drug: Microinjections of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Microinjections of HA salts of biotechnological origin, in patients from group B that completed 10 months of treatment
Trial: 25539986
Drug: Saline solution
RxNorm normalized name: Unisol 4 Saline Solution
DrugBank: Sodium chloride (DB09153)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Saline solution injected into the dorsum of the other hand (control)
Trial: 23451990
Drug: nHA with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: nHA with 24% EDTA treatment
Trial: 23451990
Drug: Composite graft
RxNorm normalized name: polyvinyl alcohol graft polyethylene glycol copolymer (3:1; 45000 MW)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Composite graft of nHA and β‐TCP with 24% EDTA treatment
Trial: 19057413
Drug: Olanzapine (2.5-20.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Olanzapine (2.5-20.0 mg/day)
Trial: 11238495
Drug: MK-677 (25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MK-677 (25 mg) plus alendronate (10 mg)
Trial: 2977527
Drug: Zoladex (3.6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zoladex (3.6 mg depot administered every four weeks for 3 times)
Trial: 2977527
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (300 mg diethylstilbestrol diphosphate orally daily for 12 weeks or orchidectomy)
Trial: 26631691
Drug: Oral moisturizing
RxNorm normalized name: MOISTURIZER
DrugBank: Homosalate (DB11064)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral moisturizing jelly (OMJ)
Trial: 22922775
Drug: Prednisone (PRED)
RxNorm normalized name: Prednisone
DrugBank: Prednisone acetate (DB14646)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Prednisone (PRED) 40 mg/m²/day for 28 days
Trial: 22922775
Drug: Dexamethasone (DEX)
RxNorm normalized name: Dexamethasone
DrugBank: Dexamethasone acetate (DB14649)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Dexamethasone (DEX) 6 mg/m²/day for 28 days
Trial: 11246736
Drug: Cisplatin-based combination
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cisplatin-based combination chemotherapy
Trial: 18685360
Drug: Addition of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Addition of a third agent to doublet combinations
Trial: 18685360
Drug: New drugs
FDA approved: no
EMA approved: no
PMDA approved: no
Description: New drugs (pemetrexed and vinflunine)
Trial: 10442371
Drug: UFT (300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: UFT (300 mg/day) plus oral calcium folinate (90 mg/day) and vinorelbine (15 mg/m2)
Trial: 7531223
Drug: PVP16B (cisplatin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PVP16B (cisplatin 20 mg/m2 on days 1 to 5 + etoposide 100 mg/m2 on days 1 to 5 + bleomycin 30 IU/wk for 9 consecutive weeks)
Trial: 7531223
Drug: PVP16 (cisplatin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PVP16 (cisplatin 20 mg/m2 on days 1 to 5 + etoposide 100 mg/m2 on days 1 to 5)
Trial: 2193271
Drug: estrone sulfate
RxNorm normalized name: Estrone sulfate
DrugBank: Estrone sulfate (DB04574)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: estrone sulfate 0.625 mg
Trial: 2193271
Drug: estrone sulfate
RxNorm normalized name: Estrone sulfate
DrugBank: Estrone sulfate (DB04574)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: estrone sulfate 1.25 mg
Trial: 387204
Drug: 5 FU
RxNorm normalized name: i5 Functional Food Nutritional Powder for Suspension (Vanilla Delight)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 FU infusion with mitomycin-C
Trial: 387204
Drug: 5 FU
RxNorm normalized name: i5 Functional Food Nutritional Powder for Suspension (Vanilla Delight)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 FU infusion with methyl-CCNU
Trial: 31389859
Drug: Group A1
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group A1 (80 kVp, 40 mL CM, iterative reconstruction)
Trial: 31389859
Drug: Group A2
RxNorm normalized name: PROCYANIDIN A2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group A2 (80 kVp, 40 mL CM, AI-based noise reduction)
Trial: 31389859
Drug: Group B
RxNorm normalized name: Blood group B IgM
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group B (120 kVp, 80 mL CM, iterative reconstruction)
Trial: 29995458
Drug: Vitamin C
RxNorm normalized name: Vitamin C
DrugBank: Sodium ascorbate (DB14482)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin C (2 g/day) for 6 days
Trial: 25185586
Drug: Individualised physical
RxNorm normalized name: hypochlorite
DrugBank: Hypochlorite (DB11123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Individualised physical activity on prescription
Trial: 16388724
Drug: Oral terbinafine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral terbinafine (250 mg/day) for 6 weeks
Trial: 1537129
Drug: Alteplase plus
RxNorm normalized name: Alteplase
DrugBank: Alteplase (DB00009)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Alteplase plus heparin
Trial: 1537129
Drug: Heparin with
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Heparin with adequate anticoagulation
Trial: 1537129
Drug: Heparin with
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Heparin with patent vessels
Trial: 1537129
Drug: Heparin with
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Heparin with recurrent ischemia
Trial: 1537129
Drug: Heparin with
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Heparin with left ventricular thrombosis
Trial: 27460620
Drug: Group Coping-Oriented
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group Coping-Oriented Therapy (COP)
Trial: 27460620
Drug: Supportive Therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Supportive Therapy (SUP)
Trial: 20393432
Drug: Rotigotine, a
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rotigotine, a dopaminergic drug, dosage and duration not specified
Trial: 15714982
Drug: Docetaxel as
RxNorm normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Docetaxel as a single agent
Trial: 15714982
Drug: Docetaxel combined
RxNorm normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Docetaxel combined with estramustine or other antimicrotubular agents
Trial: 15714982
Drug: Docetaxel in
RxNorm normalized name: docetaxel Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Docetaxel in combination with prednisone
Trial: 10377207
Drug: fluticasone metered
RxNorm normalized name: fluticasone Metered Dose Inhaler
FDA approved: no
EMA approved: no
PMDA approved: no
Description: fluticasone metered dose inhaler (pMDI) 250 microg, 8 puffs
Trial: 8710072
Drug: Tacrine >
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tacrine > 80 mg/d
Trial: 8710072
Drug: Tacrine >
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tacrine > 120 mg/d